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Acute kidney injury (AKI) is a major health care condition with limited current treatment options. Within
this context, stem cells may provide a clinical approach for AKI. Moreover, a synthetic compound previously
developed, hyaluronan monoesters with butyric acid (HB), able to induce metanephric differentiation, forma-
tion of capillary-like structures, and secretion of angiogenic cytokines, was tested in vitro. Thereafter, we
investigated the effects of human mesenchymal stem cells from fetal membranes (FMhMSCs), both treated
and untreated with HB, after induction of ischemic AKI in a rat model. At reperfusion following 45-min
clamping of renal pedicles, each rat was randomly assigned to one of four groups: CTR, PBS, MSC, and
MSC-HB. Renal function at 1, 3, 5, and 7 days was assessed. Histological samples were analyzed by light
and electron microscopy and renal injury was graded. Cytokine analysis on serum samples was performed.
FMhMSCs induced an accelerated renal functional recovery, demonstrated by biochemical parameters and
confirmed by histology showing that histopathological alterations associated with ischemic injury were less
severe in cell-treated kidneys. HB-treated rats showed a minor degree of inflammation, both at cytokine and
TEM analyses. Better functional and morphological recovery were not associated to stem cells’ regenerative
processes, but possibly suggest paracrine effects on microenvironment that induce retrieval of renal damaged
tissues. These results suggest that FMhMSCs could be useful in the treatment of AKI and the utilization of
synthetic compounds could enhance the recovery induction ability of cells.
Key words: Stem cells; Acute kidney injury (AKI); Mesenchymal stem cells (MSCs); Renal function;
Renal cell biology
INTRODUCTION and its incidence is growing over time. The incidence of
AKI is variable relative to the population examined, up
to 288 cases per 100,000 population and with an 11%Acute kidney injury (AKI) represents an increasingly
frequent clinical condition in the field of Nephrology yearly increase (43). Moreover, AKI is a prognostic fac-
tor statistically related to mortality, hospitalization dura-and Intensive Care Units. Although treatment with novel
drugs and advanced life support techniques have im- tion, and quality of life. In particular, in-hospital mortal-
ity is very high, especially in patients who need renalproved survival of patients with severe organ impair-
ment (often characterized also by a multiorgan failure), replacement therapy, exceeding 50% (20,27). Research
is very active in defining standards and support technol-AKI remains in any case a major public health burden
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ogies in order to prevent, diagnose, and treat AKI. A under gravity for 5 min. Each supernatant was trans-
ferred to a fresh tube, neutralized with fetal bovine se-revolutionary strategy of intervention may be repre-
sented by the application of regenerative medicine. rum (FBS), and then spun at 1500 rpm for 10 min. Each
pellet was resuspended in 5 ml of DMEM containingIn a probable future, stem cells may restore damaged
organs in their complexity, but now they allow repairing 20% FBS, 10 U/ml penicillin, and 100 µg/ml streptomy-
cin. Human mesenchymal stem cells from fetal mem-a variety of injuries, mainly acting as “pharmacological”
agents. branes (FMhMSCs) were seeded into 25-cm2 flasks and
grown at 37°C in 5% CO2. Nonadherent cells were re-There are many articles showing how stem cells may
interact with adult tissues. In particular, mesenchymal moved after 1 week and medium (with 10% FBS) was
changed subsequently every 4 days.stem cells (MSCs) are well characterized, easily avail-
able, and have been extensively studied both in vitro and Flow Cytometry Analysis. The fibroblast-like cells
in vivo (4,6,9,12,13,31–34,48,49). It has been demon- obtained from fetal membrane cultures were harvested
strated that MSCs are able to promote tissue repair in by treatment with 0.08% trypsin-EDTA and incubated
many experimental settings. Here we employed human with 1 µg/106 cells antibodies conjugated with different
MSCs to treat functional ischemia/reperfusion (I/R) in- fluorescent probes for 40 min at 4°C in the dark. Thejury in a wild-type rat model, in order to determine the antibodies used were: CD105 (Chemicon International,
ability of MSCs to repair a nonstructural damage. Fur- Millipore, Billerica, MA), CD73, CD90, CD166, CD14,
thermore, on the basis of encouraging experiences on CD34, CD44, and CD45 (Becton Dickinson, Franklin
heart models (41,42), we employed MSCs treated with Lakes, NJ). After washing with PBS, cells were ana-
novel differentiating agents, such as monoesters of hya- lyzed on a flow cytometer (FACSAria, Becton Dickin-
luronan with butyric acid (HB), in order to verify son) by collecting 10,000 events and the data analyzed
whether MSC preconditioning could led to further en- using the FACSDiva Software (Becton Dickinson).
hancements in I/R functional recovery. Hyaluronic acid Cytofluorimetric analysis of FMhMSCs confirmed a
represents an efficient targeting system, because its re- mesenchymal antigenic profile (CD29+, CD166+, CD73+,
ceptor CD44 is expressed on a variety of cells and li- CD90+, CD105+, CD44+, CD34−, CD45−, CD14−) as
gand–receptor interaction leads to complex internaliza- shown in Table 1, and the culture with specific media
tion of transported molecules (18), such as butyric acid, triggered the differentiation in osteocytes, adipocytes,
a histone deacetylase inhibitor, which activates expres- and chondrocytes, demonstrating the mesenchymal na-
sion of several genes, including those responsible for ture of the isolated population. In particular, the pres-
growth control and cell differentiation (25). ence of the receptor of hyaluronic acid CD44 in more
The aim of the study was to observe the effects of than 98% of cells strengthens the rationale for the use
administration of human MSCs on recovery of renal of these esters.
function following I/R damage in a rat model, confirm- Adipogenic Differentiation. To induce adipocyte dif-ing our observations by histology and electron micros- ferentiation, cells were cultured using Mesenchymal
copy. Additionally, an objective to accomplish was to Stem Cell Adipogenesis Kit (Chemicon International)detect and characterize possible positive effects induced
according to the manufacturer’s instructions. Theby pretreatment of stem cells with novel differentiating growth medium was replaced every 2–3 days. After 2–3
agents.
MATERIALS AND METHODS Table 1. Percentage of Antigen Expression in Human
Mesenchymal Stem Cells From Fetal Membranes (FMhMSC)Preliminary Studies and Transdifferentiation Procedure
Antigen % Positive FMhMSCCell Isolation. According to the policy approved by
the local Ethical Committee, all tissue samples were ob-
CD73 95 ± 4tained after informed consent. Term placentas collected CD105 96 ± 3from caesarian sections were rapidly rinsed in phos- CD29 98 ± 1
phate-buffered saline (PBS) containing penicillin and CD166 95 ± 2
streptomycin and used immediately. Pieces from fetal CD44 98 ± 2
membranes were minced and digested for 10 min in CD14 0
Dulbecco’s modified Eagle’s medium (DMEM) with CD34 0
CD45 00.25% trypsin-EDTA, 10 U/ml DNaseI, and 0.1% colla-
genase (Sigma-Aldrich Co., St. Louis, MO). Tissues
FMhMSCs are positive for CD73, CD105, CD29, CD166, and CD44
were pipetted vigorously up and down avoiding foam and negative for CD14, CD34, and CD45, typical markers of hemato-
poiesis.for 5 min; larger pieces of tissue were allowed to settle
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Table 2. Primer Sequences for Real-Time PCRweeks of culture the cells contained neutral lipids in fat
vacuoles; they were fixed in 10% formalin and stained
Gene Sense Primer Sequence
with fresh oil red-O solution (Sigma-Aldrich Co.) (Fig. 1a).
SCD forward 5′-GGTTTCACTTGGAGCTGTG-3′Osteogenic Differentiation. Cells were cultured in
reverse 5′-GCCATGCAATCAATGAAGAA-3′DMEM supplemented with 10% FBS until they were
80–90% confluent. To induce osteogenic differentiation CD24 forward 5′-GCCAGTCTCTTCGTGGTCTC-3′
cells were plated in osteogenesis induction medium reverse 5′-TGTTTTTCCTTGCCACATTG-3′
(Mesenchymal Stem Cell Osteogenesis Kit, Chemicon
Cadh11 forward 5′-ATCGTCATTCTCCTGGGTTG-3′International) and maintained for 14–17 days, replacing
reverse 5′-GCCACCACATAGAGGAAAGG-3′
the medium every 2–3 days, according to manufacturing
YWHAQ forward 5′-CTTTTGATGAGGCCATTGCT-3′instructions. To demonstrate osteogenic differentiation,
reverse 5′-TCCTGCACTGTCTGATGTCC-3′the cultures were fixed and von Kossa stained (Fig. 1b).
RARα forward 5′-GAGATGGATGATGCGGAGAC-3′Chondrogenic Differentiation. To induce chondro-
reverse 5′-TCCGCACGTAGACCTTTAGC-3′genic differentiation, aliquots of 2.5 × 105 cells were
pelleted in polypropylene conical tubes in differentiation EWSH forward 5′-CCTGGACAAGGAAACAGGAA-3′
basal medium-chondrogenic (Poietics, Lonza, Basel, reverse 5′-TCCGAGCAAGGGAGACTTTA-3′
Switzerland) supplemented with hMSC Chondrogenic
SCD, stearoyl CoA desaturase; Cadh1, cadherin 11; YWHAQ, 14-3-3Single Quotes (Poietics, Lonza) and transforming protein theta; RARα, retinoic acid receptor α; EWSH, Ewing sarcoma
growth factor-β3 (TGF-β3; Lonza). This medium was homolog.
replaced every 2 days for 3–4 weeks. Pellets were for-
malin-fixed, embedded in paraffin, examined morpho-
logically, and immunostained for type II collagen SYBR Green I, Roche Diagnostics). Primer sequences
(Chemicon International), using Vectastain elite ABC used for real-time PCR are reported in Table 2.
kit (Vector Laboratories, Burlingame, CA) (Fig. 1c). Amplification included initial denaturation at 95°C
for 10 min, 45 cycles of denaturation at 95°C for 10 s,Gene Expression. Cells were treated with HB or
HBR (hyaluronan mixed esters of butyric and retinoic annealing at 55–65°C for 6–10 s, and extension at 72°C
for 10 s performed at a temperature transition rate ofacid) at the concentrations of 1, 1.5, 2, and 3 g/L for 7
days. 20°C/s. Fluorescence was measured at the end of each
extension step. Specificity of the product was deter-Total RNA was isolated using TRIzol reagent (In-
vitrogen, Carlsbad, CA), following the manufacturer’s mined by a melting curve analysis.
After treatment with the esters, we analyzed the tran-instructions. For RT-PCR, cDNA was synthesized in a
21-µl reaction volume with 2 µg of total RNA and scription levels of genes expressed at the first stages of
nephrogenic differentiation, at the level of metanephricSuperScript II RT (Invitrogen). In order to assess mRNA
expression of genes specific for the metanephric mesen- mesenchyme. The results revealed that the use of HBR
did not increase expression of the considered genes afterchyme, 20 ng cDNA was used for real-time RT-PCR
performed with a Lightcycler system (Roche Diagnos- 7 days of treatment (data not shown). This result was
partially expected, because precedent experiments hadtics, Basel, Switzerland) and with the SYBR Green fast
start kit (Lightcycler FastStart DNA MasterPLUS shown a selected action of this ester to induce cardio-
Figure 1. Induction of classical mesenchymal differentiation in human mesenchymal stem cells
from fetal membranes (FMhMSCs). (a) Adipogenic differentiation; (b) osteogenic differentiation;
(c) chondrogenic differentiation. Scale bars: 100 µm.
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genesis (41). We believed interesting in any case to test We assessed the secretion of angiogenic cytokines
[follistatin (FST), hepatocyte growth factor (HGF),this molecule, because retinoic acid carries out an im-
portant role during renal development. granulocyte-colony stimulating factor (G-CSF), interleu-
kin-8 (IL-8), leptin, CD31, platelet-derived growth fac-Conversely the treatment with HB, with a peak at
the concentration of 1 mg/ml, increased significantly the tor (PDGF-BB), vascular endothelial growth factor
(VEGF), and angiopoietin] with Bio-Plex ProTM angio-transcription levels of all the genes analyzed (t-test, p <
0.05) (Fig. 2). genesis assay. This is a magnetic bead-based multiplex
assay allowing the measurement of angiogenesis bio-Endothelial Differentiation. Based on the fact that
markers in cell culture supernatant. Samples were pre-
endothelial repair would represent an important goal in pared according to the manufacturer’s instructions. Data
the prevention of chronic nephropathies, we tested the from the reaction were then acquired using the Luminex
ability of FMhMSC to differentiate in capillary-like
system. The concentrations values were normalized on
structures. Analysis of capillary formation was per-
total protein amount.formed using Matrigel (ECM gel E1270, Sigma-Aldrich Results are depicted in Figure 4. FST is an inhibitorCo.), a semisolid medium. Fifty microliters of gel matrix
of inflammation and a proangiogenic factor (19). It
solution, diluted 1:2 with DMEM, was applied to each binds to activins, promoting tissue regeneration in the
well on a 96-well plate and incubated for 1 h at 37°C; liver and kidney (24). FST levels (Fig. 4a) were signifi-1 × 103 cells were then suspended in 50 µl of DMEM,
cantly higher in the cells pretreated with HB, compared
or HB 1 g/L in DMEM, plated onto the gel matrix and
to control cells. This effect appeared at 48 h and main-incubated at 37°C. Capillary-like structures were ob-
tained up to 14 days. The peak of release was observed
served by optical microscopy after 2 h and at regular
at 7 days, followed by a decrease, probably due to aintervals during the following 24 h.
saturation effect or negative feedback. In any case, theFigure 3 shows the results of the Matrigel analysis.
treatment with HB led to a significant increase of releaseWe observed that FMhMSCs treated with HB (1 mg/
also at 14 days if compared to untreated cells.
ml), were able to migrate and align themselves in Matri- HGF is one of the most important angiogenic andgel to form tubular-like structure already after 3–4 h
antiapoptotic cytokines (26). G-CSF is involved in the(Fig. 3b), differently than untreated cells that exhibited
recruitment of granulocytes and stem cells from bone
capillary-like features only after 8 h and at remarkably
marrow (35). Platelet endothelial cell adhesion mole-lower extent (Fig. 3a).
cule-1 [PECAM-1 (CD31)] is a marker of differentiating
endothelial cells, involved in inflammatory response, in-Production of Angiogenic Cytokines. We tested the
ability of FMhMSCs pretreated with HB to induce angi- ducing tissue repair and vessel reconstruction (46). HB
resulted in an increased of HGF (Fig. 4b), G-CSF (Fig.ogenesis through secretion of cytokines.
Figure 2. The treatment with HB (hyaluronan monoesters with butyric acid) 1 mg/ml is the most
effective to increase the levels of expression of metanephric markers analyzed.
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Figure 3. (a) Organization of untreated cells on capillary-like structures on semisolid medium after
8 h. (b) Cells pretreated with HB 1 mg/ml show an increased capillary-like structure formation
after 4 h. Scale bars: 100 µm.
4c), and PECAM-1 (Fig. 4d) release, compared to the it is implicated in repair of damaged vessels and genera-
tion of new ones (10). This cytokine (Fig. 4e) and VEGFcontrol, with a zenith at 14 days.
HB did not affect the secretion of IL-8 (Fig. 4f), a (Fig. 4g) revealed a common pattern, with a rise in their
release up to 14 days, but without any difference com-chemokine involved in inflammatory response and angi-
ogenic activity in tumors. pared to the control.
Leptin is produced by adipose tissue and has an im-PDGF-BB is secreted by platelets, it stimulates the
growth of preexisting vessels, and together with TGF-β portant role in angiogenesis process increasing the levels
Figure 4. Analysis of secretion of angiogenic cytokines comparing FMhMSCs (light bars) and HB-treated FMhMSCs (black bars)
up to 14 days. HB treatment was performed at a concentration of 1 g/L. (a) Follistatin (FST); b) hepatocyte growth factor (HGF);
c) granulocyte-colony stimulating factor (G-CSF); d) platelet endothelial cell adhesion molecule-1 (PECAM-1 or CD31); e) platelet-
derived growth factor (PDGF); f) interleukin-8 (IL-8); g) vascular endothelial growth factor (VEGF); h) leptin; i) angiopoietin.
Values are normalized to total protein amounts. *p < 0.05.
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of VEGF (8). Angiopoietin is a growth factor able to Bologna. Thirty-six male Sprague-Dawley rats (weigh-
ing 230–280 g) were used for this experiment. The ani-promote angiogenesis and the formation of new blood
vessels from preexisting ones (36). Both leptin (Fig. 4h) mals were anesthetized with xylazine-tiletamine/zola-
zepam (Zoletil, Virbac, Carros, France) and placed onand angiopoietin (Fig. 4i) were not initially expressed
by control or treated cells, but they were secreted at 7 a deltaphase heating pad (2Biol, Besozzo, Italy). The
abdominal cavity was accessed transperitoneally throughdays and 72 h, respectively. The release of leptin was
higher in cells treated with HB compared to control, at a midline xyfopubic incision to gain access to both kid-
neys. All animals underwent an ischemia-reperfusion7 days. We could not observe any difference in angio-
poietin secretion. damage by bilateral 45-min clamping of both renal pedi-
cles. At reperfusion each animal was randomly assignedThe potentiality for nephrogenic transdifferentiation
of cultured FMhMSCs after treatment with HB was also to one of four therapy groups: CTR—control group;
PBS—administration of 0.15 ml of PBS; MSC—admin-tested. We observed that treatment with 1 g/L of HB
induced the highest expression of genes specific for istration of 1 × 106 FMhMSCs suspended in 0.15 ml of
PBS; MSC-HB—administration of 0.15 ml suspensionmetanephric mesenchyme. Furthermore, cells showed
the ability of forming capillary-like structures and en- of 1 × 106 FMhMSCs pretreated with esters of hyaluro-
nic and butyric acids (1 g/L for 14 days). PBS and stemhanced secretion of the angiogenic cytokines considered,
with elevated production of anti-inflammatory mole- cells were injected directly into the cortex of only the
left kidney. Right kidneys served as intragroup controls.cules (Fig. 4).
Intraparenchymal administration was performed with a
Study Protocol 24-gauge syringe in 4–5 injections of 0.03–0.05 ml each
at different locations along the lateral aspect of theTaken together, the preliminary results of the in vitro
kidney.studies on HB-treated FMhMSCs suggest that the cells
are able to express markers of nephrogenic differentia-
Histology and Immunohistochemistry. After animalstion and to form capillary-like structures: we then tested
sacrifice, both kidneys were recovered and cut alongwhether these cells could help tissue repair in a model
median–longitudinal axis by a razor blade, fixed in 10%of ischemic renal acute damage in wild-type rats.
buffered formalin, and then embedded in paraffin; 4 µm-Study Design. Twenty-four animals were followed to thick-sections were used for histological and immuno-7 days of survival. The animals were monitored in meta- histochemical analysis. Each section was stained withbolic cages to monitor urine output. At days 1, 3, 5, and hematoxylin and eosin and observed under a light mi-7 (i.e., at sacrifice) urine and blood samples were col-
croscope (LM) to quantify the amount of renal damagelected and analyzed by standard laboratory methodolo-
using the histological score proposed by Karpinski et al.gies. Urinary sodium, creatinine, and urea were determined (15).
and urine output was registered. Serum creatinine, urea, Immunohistochemical study was performed with an
and sodium were measured. Creatinine clearance and
anti-human mitochondria antibody (Chemicon Interna-fractional excretion of sodium were calculated using stan- tional) and a non-biotin-amplified method (NovoLinkTMdard formulas. Both kidneys of each animal underwent Polymer Detection System, Novocastra Laboratorieshistological evaluation with light microscopy to assess re- Ltd., Newcastle Upon Tyne, UK) to evaluate the pres-
sidual renal damage. To quantify the amount of damage
ence of the administered stem cells in the tissue. Briefly,
we used an histological score proposed by Karpinski et tissue sections were deparaffinated with xylene, rehy-
al. (15) that takes glomerular, tubular, interstitial, and vas- drated through a series of graded ethanol, and rinsed in
cular components into account. Immunohistochemistry distilled water. Antigens were unmasked with citrate
assays were performed with an anti-human mitochondria buffer pH 6.0, at 120°C, 1 atm for 21 min; endogenous
antibody (1:100, Chemicon International) to detect and peroxidase activity was neutralized using a Novocas-localize the administered stem cells in the tissue. traTM Peroxidase Block and washed with Tris-bufferedAn additional 12 animals were sacrificed at 24 h from
saline (TBS) 1×. After that, the slides were incubated
reperfusion, in order to study premature response to
with NovocastraTM Protein Block for 5 min in a wetdamage. In these animals, equally randomly divided into
chamber to reduce the nonspecific binding of primary
the four treatment arms, blood samples were harvested
antibody and polymer reagent, and rinsed in TBS 1×.preischemia and at 1, 6, and 24 h postischemia. At sacri- The samples were subsequently incubated with thefice kidneys were fractioned and prepared for histologi-
monoclonal antibodies (mAb) against anti-human mito-
cal and immunohistochemical analyses.
chondria (1:100, Chemicon International) in PBS/1%
bovine serum albumin overnight at 4°C. After removalSurgical Procedure. All animal experiments were
approved by Bioethics Committee of the University of of unbound antibody, the slides were incubated for 30
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min at RT with NovocastraTM Post Primary Block to en- ferences in the timing of functional recovery. The two
groups of rats treated with cells (MSC and MSC-HB),hance penetration of the next polymer reagent, rinsed in
TBS 1×, and incubated with NovoLinkTM Polymer for in particular, presented both a less severe AKI and a
rapid course.30 min at RT. Further, the sections were exposed to the
substrate/chromogen 3,3′-diaminobenzidine (DAB) pre- Results are summarized in Figure 5. Cell-treated
groups had significantly lower serum creatinine (Fig. 5a)pared from NovocastraTM DAB Chromogen and Novo-
LinkTM DAB Substrate Buffer, rinsed in distilled water, and urea levels (Fig. 5b) compared to the control groups
CTR and PBS (p < 0.05). Creatinine clearance (Fig. 5c)and counterstained with Gill’s hematoxylin. Subse-
quently, the samples were dehydrated, coverslipped, and on day 1 was markedly reduced in all groups, but at day
7 it returned to normal levels. MSC and MSC-HBviewed in a LM using the Image-Pro Plus program.
Negative control was obtained by omitting the primary groups recovered renal function, as expressed by creati-
nine clearance, significantly faster than the controlsmAb.
(p < 0.05).Electron Microscopy. Specimens from each kidney
Fractional excretion of sodium (FE-Na) (Fig. 5d)were isolated from the cortical zone and fixed in glutar-
peaked to abnormal levels at day 1 in control groups,aldehyde 2.5% buffered in phosphate 0.1 M. After a
while cell-treated rats maintained normal values, withpostfixation in osmium tetroxide 1% in cacodylate
differences characterized by a high statistical signifi-buffer, the samples were dehydrated in graded ethanol
cance (p < 0.001). Measurements of FE-Na resultedand embedded in araldite. Ultrathin sections were coun-
within the normal levels in all groups. Serum sodiumterstained in uranyl acetate and lead citrate before obser-
levels dropped significantly on day 1 in controls, whilevation with a Philips 410 transmission electron micro-
retaining normal levels in the treated groups (p < 0.05).scope.
On successive determinations natremia levels did notCytokine Secretion Analysis. Blood samples were an- differ among the groups.
alyzed using MilliplexTM Map Rat Cytokine/Chemokine Urine osmolarity (Fig. 5e) was reduced on day 1 inkit (Millipore) for the following cytokines: VEGF, gran-
all rats and rose from day 1 to day 7 with no significant
ulocyte-macrophage colony stimulating factor (GM-CSF), differences between the groups. A trend toward a fasterinterferon (IFN-γ), IL-1α, IL-1β, IL-6, IFN-inducible
rise of osmolarity, however, could be observed in MSCprotein-10 (IP-10), monocyte chemotactic protein-1
and MSC-HB groups compared to the control groups.(MCP-1), and macrophage inflammatory protein-1α Urinary protein levels (Fig. 5f) were not significantly(MIP-1α). Twenty-five microliters of sample per well different among the groups.
was used. Cytokine analysis was performed following
the manufacturer’s instructions. Data were normalized Histology and Immunohistochemistry
to preischemia values. As shown in Figure 6 (left panel), we observed dif-
Statistical Analysis. For in vitro study, statistical ferent grades of renal injury at 24 h post-I/R with pri-
analysis was performed by using a one-way analysis of marily tubular necrosis, epithelium loss, swelling, bleb-
variance (ANOVA) and assuming a value of p < 0.05 bing, and hyaline casts; tubular injury was usually
as the limit of significance. For in vivo study, data are patchy; glomeruli were characterized by minor damages.
expressed as means (95% CI). Statistical analyses were Kidney biopsies scored according to Karpinski et al.
performed for each time point with ANOVA on rank (15) showed moderately injured right and left organs in
with Tukey post hoc test to evaluate for differences be- the CTR group (mean right + left score 2.17 ± 0.68 and
tween renal score. A value of p < 0.05 was assumed as mean left score 2.17 ± 0.72). Similar values were re-
the limit of significance. The statistical analyses were corded for the PBS group with mean right + left score
performed using SAS 9.1 software (SAS Institute Inc., of 1.89 ± 0.78 and mean left score of 2.00 ± 0.63, while
Cary, NC). MSC (mean right + left score 1.22 ± 0.67 and mean left
score 1.50 ± 0.55) and MSC-HB (mean right + left scoreRESULTS 1.22 ± 0.67 and mean left score 1.17 ± 0.75) had signifi-
Recovery From Renal Damage cantly lower scores when compared to CTR (p < 0.05).
No significant differences were observed between rightParameters describing renal function show that the
peak of maximum functional decrease was at 24 h from and left kidneys with a trend for lower injury scores in
left (compared to right) kidneys of MSC-HB rats (p >induction of renal damage. This condition of AKI im-
proved at 3 and 5 days and renal function returned to 0.05). Major reparative phenomena were observed
mostly at 7 days post-I/R, with large hyperchromatic nu-normal levels at 7 days from induction of ischemia-reper-
fusion (I/R) damage. Even though this trend was present clei, basophilic staining of tubular epithelial cytoplasm,
and flattening of the tubular epithelial cells. Overall, tu-in all four groups, there was evidence of significant dif-
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Figure 5. Analysis of biochemical parameters to evaluate renal function at 1, 3, 5, and 7 days post-I/R. (a) Serum creatinine, (b)
serum urea, (c) creatinine clearance, (d) fractional excretion of sodium, (e) urine osmolarity, (f) proteinuria. *p < 0.05, MSC and
MSC-HB versus CTR and PBS. p < 0.05, MSC-HB only versus CTR and PBS. CTR, control group; PBS, PBS administration;
MSC, administration of FMhMSCs; MSC-HB, administration of FMhMSCs pretreated with hyaluronic and butyric acids.
bular injury was minimal and a significantly decreased glomerular levels. At 24 h from I/R injury, moderate to
severe alterations were detected mainly in the tubularrenal score was recorded both in right and left kidneys
(CTR: mean right + left score 1.67 ± 0.51, mean left compartment: in particular CTR specimens were charac-
terized by the presence of cell remnants in the tubularscore 1.67 ± 0.58; PBS: mean right + left score 1.75 ±
0.89, mean left score 1.75 ± 0.96; MSC: mean right + lumen and by several epithelial cells with degenerative
alterations and loss of organelles. The glomerular com-left score 1.00 ± 0.53, mean left score 0.83 ± 0.41;
MSC-HB: mean right + left score 0.75 ± 0.46, mean left partment was well preserved from the ischemic insult.
MSC rat samples revealed moderate degenerative as-score 0.67 ± 0.51). Representative images of histological
analysis at 7 days are showed in Figure 6 (right panel). pects like those observed in the controls. The glomeruli
were normal appearing. On the contrary, MSC-HB kid-Again, the MSC and MSC-HB groups had significantly
lower scores when compared with controls (p < 0.05) neys evidenced normal tubular epithelial cells together
with presence of some mitotic figures (Fig. 9) that couldand left kidneys of the MSC-HB group had a substan-
tially normal histological appearance. be considered as a regenerative index. This result con-
firms a more rapid recovery in MSC-HB rats, as showedIn order to evaluate the presence of injected FMhMSCs
within the kidneys, immunohistochemistry with human by histological sections.
At 7 days, CTR specimens exhibited degenerativeanti-mitochondria antibody was performed in right and
left kidneys at 7 days postinjury. Immunostaining lo- changes of mitochondria characterized by dilation and
loss of electrondense matrix, and cristae appeared frag-cated human cells within the glomeruli, as well as in
periglomerular and peritubular positions (Fig. 7). The mented. These alterations seem to be likely due to an
osmotic balance dysregulation. No differences betweendistribution of positively stained cells was extremely
patchy; no particular pattern of distribution could be ob- CTR and PBS groups were detectable. The glomerular
compartment featured moderate to severe alterations ofserved: cortical and juxtaglomerular regions were irreg-
ularly stained both in left and right kidneys. Quantitative podocytes and mesangial cells, characterized by picnotic
nuclei. On the contrary, cell-treated kidneys had a nor-contribution of cell administration in renal parenchyma
was modest; thus, no cell counts were performed. mal appearing morphology at the ultrastructural level:
tubular epithelial cells showed well-shaped and com-
Transmission Electron Microscopy pletely recovered mitochondria and glomerular cells
showed normal submicroscopic morphology and archi-The electron microscopy analysis, as represented in
Figure 8, showed alterations visible both at tubular and tecture.
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Figure 6. Representative images of kidney histology at 24 h (left panel) and 7 days (right panel) from I/R damage. At 24 h there
was mainly a moderate degree of tubular injury, which was significantly ameliorated by kidney administration of MSC and HB-
treated MSC. At 7 days tubular damage was decreased in all groups and particularly in the MSC-HB group, where an almost
complete morphological recovery was seen. Hematoxylin and eosin stain; original magnification: 10×. The graphs represent mean
histological score for each group in right + left and only left kidneys. MSC, human mesenchymal stem cells from fetal membranes;
MSC-HB, MSC treated with hyaluronan monoesters and butyric acid compound. *p < 0.05. Scale bars: 100 µm.
At 7 days, kidneys of rats in the CTR group, both thelial cells can be characterized by irregular surface
with thin microvilli indicating activation of likely imma-left and right (Fig. 10a, b) displayed normal appearing
capillaries lined with thin endothelial cells and exhibit- ture cells and neoformation of vessels. Figure 11 shows
relevant details revealed by TEM analysis.ing a smooth surface.
Left and right kidneys of MSC group animals (Fig.
Cytokine Analysis10c, d) were characterized by vascular structures with a
perivascular inflammatory infiltrate, constituted by some Results of cytokine analysis in serum of rats are sum-
marized in Figure 12. Serum levels of IFN-γ (Fig. 12a)lymphocytes and monocytes. We observed endothelial
cells with dispersed nuclear chromatin and electron- were significantly lower 24 h after I/R in cell-treated
rats, compared with controls. The secretion of IP-10lucent cytoplasm with few organelles.
In the MSC-HB group, both kidneys (Fig. 10e, f, left (Fig. 12b) at this time was significantly decreased in
MSC group compared with CTR. At 24 h the levels ofand right kidney, respectively) showed vascular struc-
tures with almost similar features as in the MSC-treated IL-1β (Fig. 12 c) were significantly lower in the MSC-
HB group and IL-1α levels (Fig. 12d) were significantlyrats, but without the inflammatory infiltrate. Clear endo-
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Figure 7. Immunohistochemical (IHC) detection of human MSC at 7 days post-I/R. IHC on left and rights kidneys demonstrates
that in situ retention of MSC is minimal; MSC were seen in proximity of glomeruli (left panel), within glomeruli (central panel)
and in peritubular stroma (right panel); the insert shows a couple of intraglomerular, pericapillary intensely stained MSC; an
interesting finding was the MSC capability to target the contralateral right kidney from the site of injection. IHC with anti-human
mitochondria monoclonal antibody. Nuclei are counterstained with hematoxylin. Original magnification: 25×. Scale bars: 50 µm.
lower in MSC rats, compared to CTR. Serum levels of of sodium. Some of these parameters, which reflect the
excretory function of the kidney, indicated a better con-IL-6 (Fig. 12e) 1 h after I/R injury were significantly
lower in cell-treated groups compared with PBS and in dition in cell-treated rats. Serum creatinine levels (Fig.
5a) 1 day after treatment were lower in the MSC andMSC-HB group compared with CTR. The secretion of
this cytokine in the MSC group was maintained signifi- MSC-HB groups, compared to controls (maximum value
2 vs. 3 mg/dl). We also noticed that in cell-treatedcantly lower compared with PBS after 6 h. There was
no significant difference between the four groups in se- groups serum creatinine returned to normal levels al-
ready at day 3, whereas control rats showed full restora-rum levels of MIP-1 (Fig. 12f). Levels of MCP-1 (Fig.
12g) were significantly increased in MSC-HB group tion only at day 7. The same trend could be observed
for both serum urea levels (Fig. 5b) and creatinine clear-after 6 and 24 h compared to the PBS group, and after
1 and 6 h compared to the MSC group. Serum VEGF ance (Fig. 5c). Even FE-Na (Fig. 5d) was worst in un-
treated rats on day 1, but it had a rapid recovery after 3levels (Fig. 12h) at 1, 6, and 24 h were significantly
higher in the MSC-HB group compared to CTR and days from I/R damage, whereas in cell-treated groups it
remained stable at low levels.PBS, and at 6 and 24 h compared to MSC.
The clinical trend was confirmed by morphological
DISCUSSION studies: as expected, the histopathological alterations as-
sociated with I/R injuries were moderate in intensity,The aim of our study was first to demonstrate that
the administration of FMhMSCs in a rat model could patchy in distribution, and mainly affecting the tubular
compartment; glomeruli were almost undamaged if ana-be beneficial and lead to a faster recovery of reversible
ischemic AKI. Second, we evaluated if the pretreatment lyzed both at light and electron microscopy. Cell-treated
kidneys showed a slightly better score, compared to con-of FMhMSCs with HB could further enhance the repair
of kidney injury, given the property of HB to induce the trols. We noticed that the protective effect was acting
early and it could be detected already at 24 h from dam-secretion of cytokines and the differentiation of cells
into metanephric progenitors or capillary-like structures. age induction, as there are signs of cell proliferation in
renal tubular cells. Figure 9 demonstrates the presenceRenal function trend was ameliorating during the 7
days after induction of I/R injury in all groups of rats, of a mitosis that could be detected only in the MSC-HB
group. It is important to highlight that the cell-treatedboth untreated and treated with FMhMSCs administra-
tion. Finally, at day 7, kidney function was completely kidneys had this significant lower extent of damage al-
ready at 24 h from induction of same degree of ische-restored in all groups; however, some differences
emerged in relation to severity of renal injury and time mia: we can hypothesize an important role of cell adminis-
tration both in preventing I/R damage and promotingof recovery.
Cell-treated rats showed a less severe AKI, as it could effective repair.
Seven days after I/R injury, there was a prompt re-be evaluated 1 day after I/R injury by analyzing bio-
chemical parameters, such as serum levels of creatinine covery of tubular damage in all the groups considered;
however, cell-treated kidneys healed more efficiently,and urea, creatinine clearance, and fractional excretion
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Figure 9. TEM, 6,400×, scale bar: 10 µm. MSC-HB-treated
kidney 24 h postischemic damage. Few mitotic figures are vis-
ible among tubular epithelial cells.
particularly those injected with HB-treated FMhMSCs.
In this group, light and electron microscopy revealed an
almost complete structural recovery.
It has been demonstrated that MSCs from bone mar-
row can migrate to the site of kidney damage (11,12)
and contribute to injury recovery, especially in studies
with models of sex-mismatched bone marrow or kidney
transplantation (28,29). However, migration and homing
of MSCs are not yet fully understood even though the
production of G-CSF from renal mTAL cells (52) after
an ischemic damage and CD44–hyaluronic acid interac-
tion (11) seems to play a significant role.
The mechanisms through which exogenous MSCs
promote tissue repair are even more complex and for
many aspects controversial. Some authors indicated that
MSCs may act by transdifferentiation or cell fusion to
replace the lost cells (28,29), and this mechanism wouldFigure 8. Transmission electron microscopy (TEM), 6,400×,
scale bars: 10 µm. Kidneys of rats at 24 h (left panel, a–e) reproduce the onset of natural strategies of repair. Other
and 7 days (right panel, f–j) after ischemic damage. (a) CTR: authors, instead, indicate that only a small number of
tubular epithelial cells showing severe ischemic alterations and
cells can successfully engraft the organ and usually for
cell remnants in the luminal space. (b) MSC treated: few tubu-
a limited lapse of time (3,7,12,37,38). This suggests thatlar epithelial cells with degenerative necrotic changes. (c)
MSCs are unlikely involved in direct restoration of theMSC-HB treated: Normal looking epithelial lining of tubular
structures with a maintained architecture. (d) CTR: glomerular organ, but cells prevalently act via paracrine mecha-
architecture seems to be unaffected by ischemic insult. (e) nisms, stimulating repair from residual cells or even in-
MSC-HB: the glomerulus shows a normal appearing organiza- ducing proliferation and differentiation of organ-specifiction, comparable to control kidney. (f) CTR: tubular epithelial
stem cells. Overall our results support this view; per-cells showing submicroscopic alterations of mitochondria that
forming immunohistochemical analysis of the reper-appear swollen with fragmented cristae. (g) MSC treated: tu-
bular epithelial cell with mild degenerative changes, mainly at fused kidneys by antibody anti-human mitochondria, we
the cell surface, with partial loss of microvilli. (h) MSC-HB found that there were just a few FMhMSCs engrafting
treated: tubular epithelial cells feature normal appearing mito- the rat kidney, against the marked improvement in renal
chondria with electrondense matrix and oriented cristae. (i)
function that was observed, indicating that the adminis-CTR: glomerular structures show a maintained architecture,
tered stem cells do not contribute directly to tissue re-but some mesangial cell and podocytes are characterized by
degenerative changes. (j) MSC-HB treated: normal appearing generation. Even though the absence of clear signs of
glomerulus. regeneration seems to be in contradiction with other
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Figure 10. TEM, 6,400×, scale bars: 1 µm. Analysis of vasculature in different groups. (a) CTR
group, left kidney; (b) CTR group, right kidney; (c) MSC group, left kidney; (d) MSC group, right
kidney; (e) MSC-HB group, left kidney; (f) MSC-HB group, right kidney. In the CTR group (a,
b) normal vessels is evidenced. In the MSC group (c, d) signs of vasculature regeneration is
evidenced: the presence of dispersed nuclear chromatin and electron-lucent cytoplasm with few
organelles is a sign of activation of endothelial cells. Moreover, some leukocytes infiltrating the
tissue are observable. In the MSC-HB group (e, f) signs of neovascularization is still evident, but
no inflammation is highlighted.
Figure 11. TEM, 6,400×, scale bars: 1 µm. Details of TEM analysis. (a) MSC group, an endothe-
lial cell showing signs of activation. (b) MSC-HB group, a mitosis in an endothelial cell.
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Figure 12. Cytokine levels in serum of rats preischemia, 1, 6, and 24 h after induction of I/R damage. (a) Interferon (IFN-γ); b)
IFN-inducible protein-10 (IP-10); c) IL-1β; d) IL-1α; e) IL-6; f) macrophage inflammatory protein (MIP-1α); g) monocyte chemo-
tactic protein (MCP-1); h) VEGF. Data are normalized to preischemia values. *p < 0.05.
works, we observed both functional improvement and a promptly from AKI. After all, the anti-inflammatory ef-
fect of stem cells is well known, because there are sev-better architectural tissue organization.
Cytokine serum assays suggest that in the present ex- eral papers showing the ability of stem cells to reduce
both cellular and humoral immune responses (1,14,17,perimental setting FMhMSCs may restore renal function
through a paracrine mechanism most likely involving 22,23). In particular, the administration of immature
cells expressing major histocompatibility complex Ialso resident mesenchymal and tubular epithelial cells
(12). Indeed, in cell-treated groups we detected lower (MHCI) at low levels without second signal receptors,
such as costimulatory molecules CD40, CD80 andlevels of proinflammatory cytokines like IL-1α and IL-
1β, IL-6, IFN-γ, and IP10 than in controls, whereas lev- CD86, induces immune responses that support tolerance
by Treg and Th2 cell increase versus Th1 decrease, andels of factors that tend to lower the inflammatory re-
sponse, like MCP-1 and VEGF, were increased (Fig. the production of IL-4 and IL-10 anti-inflammatory cy-
tokines (29).12). A positive influence on the balance between pro-
and anti-inflammatory stimuli was particularly evident Confirming evidence of anti-inflammatory effects de-
rives also from several experiments on combined trans-in MSC-HB-treated rats (Figs. 10, 12), which recovered
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plantation of solid organs and stem cells (2,44,50,51,53). and restoring cytoplasmatic structures, all features that
ultrastructural studies documented.In this view, the use of MSCs in the treatment of AKI
could represent an important instrument for inducing a We were not able to detect large differences between
the effects of normal FMhMSCs and HB-treated cells inmodulation of the immune response and inflammation,
fundamental for a faster recovery of renal function. renal recovery, probably because the damage is preva-
lently functional with a mild organic injury, as con-In agreement with these observations and differently
from what was observed in rats treated with FMhMSCs, firmed by histological features. This was proven by the
evidence that damage was reversible per se, because un-electron microscopy did not evidence inflammatory re-
sponses in the group of rats treated with HB-FMhMSCs treated rats show full functional recovery just after 7
days from experimental procedures, with no need of ex-(Fig. 10). A statistically significant increase in anti-
inflammatory molecules was one of the elements charac- tracorporeal renal substitution techniques. Presumably,
in a setting of acute tubular necrosis (ATN), the effectterizing the preliminary in vitro steps of this study.
These results indicate that administration of mesenchy- of differentiating molecules would be to induce tissue
repair more rapidly. This eventuality needs to be verifiedmal stem cells, particularly when preconditioned with
HB, could help to reduce levels of inflammation, which by different experimental models.
Microscopy analyses showed a persisting and pre-is now recognized to be a very important factor in the
pathophysiology of ischemic AKI (5). dominantly tubular damage in every group of rats, de-
spite a full recovery of renal function. This result provesAlthough rats administered with HB-untreated and
treated MSCs were characterized by a similar recovery how renal function restoration anticipates complete tis-
sue repair and confirms that clinical parameters such asof renal function, we observed differences relative to
their ability to secrete prosurvival and differentiating creatinine, urea, and FE-Na are not accurate enough in
detecting mild and premature renal impairment, so thatgrowth factors. Experimental in vitro procedures evi-
denced a controversial direct effect of HB-treated it is necessary to find more precise methods to determine
the presence and amount of renal damage (16,40).FMhMSCs, characterized by an increment of several
factors (e.g., follistatin and HGF), but not by an influ- In summary, we demonstrated that administered hu-
man FMhMSCs can improve renal function after I/Rence on VEGF secretion. In vivo studies, instead,
showed that there is a 10 times increase in VEGF levels damage in a model of wild-type rat. This is confirmed
by the analysis of clinical parameters and morphologicalin MSC-HB rats, compared either to controls and
the MSC group. These results suggest that HB-treated aspects of injured kidneys. Our hypothesis is that the
effect of FMhMSCs could be mediated by the secretionFMhMSC effect is due not only to their secretive ability,
but also to an indirect stimulation of VEGF release, of factors, such as HGF and G-CSF, that stimulate re-
covery and it seems to influence the enhanced clinicalprobably from in situ cells. It is worth noting that VEGF
appears to be one of the most important mediators of and functional trends. We also demonstrated that differ-
entiating agents are able to induce an increased reactiv-renoprotection induced by FMhMSCs (39). Cells treated
with HB, moreover, secreted a certain number of angio- ity of FMhMSCs or a greater secretion of factors that
stimulate differentiation. Pretreatment of cells with hya-genic factors (e.g., follistatin, HGF, G-CSF, PECAM-1,
leptin), that could contribute to healing the injured kid- luronan esters could enhance FMhMSC properties in
stimulating angiogenesis and vascular regeneration andney (Fig. 3). Accordingly, at the end of the experimental
procedure, ultrastructural studies revealed not only a could potentially be useful in treatment of ATN.
There are still contrasting evidences on the contribu-complete recovery of tubular structures but also capil-
lary neoformation, as depicted in Figures 10 and 11. tion of FMhMSCs to the restoration of renal damage.
Some studies support the hypothesis for proliferationThese features were evidenced only in animals that were
administered with stem cells, both untreated and pre- and transdifferentiation of FMhMSCs at the site of dam-
age (30,45). On the contrary, many works disagree andtreated with HB.
Furthermore, these factors own important properties indicate that extrarenal cells have little or no effect at
all. An important work by Humphreys and colleaguesbesides promoting angiogenesis. For example, follistatin
is also known as an inhibitor of inflammation (19); HGF (12) reported that neither extrarenal cells nor medullary
cells contribute to tissue repair by replacing lost cells inis one of the most important antiapoptotic cytokines and
it is thought to inhibit fibrosis (47); PECAM-1 release kidney cortex. It is possible that restoration is mediated
by cortex residential progenitor cells (21,31).is able to induce tissue repair and vessel reconstruction,
beyond being a marker for endothelial differentiation Our hypothesis, however, is strongly supported by
several works: for example, To¨gel et al. demonstrated(46). The release of such factors could deeply influence
the kidney milieu, thus promoting the formation of new that administration of FMhMSCs could improve kidney
function after I/R damage and found no clue of transdif-vessels to replace the damaged ones, lowering the in-
flammation status, protecting renal cells from apoptosis, ferentiation of cells; a paracrine effect was suggested
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